ELISA test to detect CDKN2A (p16INK4a) expression in exfoliative cells: A new screening tool for cervical cancer

Molecular Diagnosis and Therapy

Volumn 12, Issue 6, 2008, Pages 395-400

  Ding, Li ^a   Zou, Xian Jin ^a   Ao, Jin E ^a   Yao, Ai Xiang ^a   Cai, Lan ^a  

^a Jingmen Hubei Province First Peoples' Hospital   (China)

Author keywords

Biomarkers; Cancer; Cervical cancer; Diagnostics; Immunoassay; In vitro diagnostic tests

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ADULT; AGED; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

GOSSYPIUM HIRSUTUM;

EID: 57349111171     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.2165/1250444-200812060-00006     Document Type: Article

References (27)

1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003; 9 (5): 348-59
2. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008, 110: S4-7
3. Zhao EF, Bao L, Li C, et al. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years [in Chinese]. Di Yi Jun Yi Da Xue Xue Bao 2005; 25 (6): 605-9
4. Lazcano-Ponce EC, Moss S, Alonsode Ruiz P, et al. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res 1999; 30: 240-50
5. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996; 334: 1030-8
6. Jacobs MV, Snijders PJF, Voorhorst FJ, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999, 503
7. Goldie SJ, Kuhn J, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285 (24): 3107-15
8. INK4a as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003; 56: 56-63
9. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E and p16 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91
10. INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84
11. INK4a expression and human papillomavirus in cervical precancer/cancer [in Chinese]. Chin J Obstet Gynecol 2004; 39 (9): 625-6
12. INK4a in cell lysates obtained from cervical samples. Cancer 2006; 107: 2307-13
13. Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours: pathology and genetics. Tumours of the breast and female genital organs [Chinese translation]. Lyon: World Health Organization, 2006
14. INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004; 35 (6): 689-96
15. O'Connor DM. The use of p16 as a marker for cervical cancer precursor lesions: a review. J Low Genit Tract Dis 2007; 11 (2): 67-8
16. Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005; 46 (5): 597-613
17. Marjoniemi VM. Immunohistochemistry in gynaecological pathology: a review. Pathology 2004; 36: 109-19
18. INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007; 26 (3): 223-8
19. Yildiz IZ, Usubütün A, Firat P, et al. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 2007; 203 (6): 445-9
20. Kelly MJ, Otterson GA, Kaye FJ, et al. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 1995; 63: 22-230
21. Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004; 4: 58
22. INK4a as an adjunct test in liquid-based cytology. Anal Quant Cytol Histol 2003; 25 (1): 8-11
23. Guo M, Hu L, Baliga M, et al. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2004; 122 (6): 894-901
24. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999; 96 (22): 12754-9
25. Knesel BW, Dry JC, Wald-Scott C, et al. Preliminary evaluation of a cervical self-sampling device with liquid-based cytology and multiparameter molecular testing. J Reprod Med. 2005; 50 (4): 256-60
26. Saqi A, Pasha TL, McGrath CM, et al. Overexpression of p16INK4a in liquid-based specimens(SurePath) and marker of cervical dysplasia and neoplasis. Diagn Cytopathol 2002; 27 (6): 365-70
27. Ferreccio C, Bratti MC, Sherman ME, et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 815-23